| Status | Study |
| Recruiting |
Study Name: Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Adult T Cell Lymphoma (ATL) Condition: Adult T-Cell Lymphoma (ATL) Date: 2016-11-01 Interventions: Drug: HBI-8000 Oral, twice weekly |
| Recruiting |
Study Name: Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma Condition: Adult T-cell Leukemia-Lymphoma ATLL Date: 2016-04-10 Interventions: Drug: Belinostat Belinostat wi |
| Recruiting |
Study Name: Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) Condition: Leukemia, Adult T-Cell HTLV I Associated T Cell Leukemia Date: 2016-02-20 Interventions: Biological: IL-15 plus alemtuzumab rhIL-15 by s.c. injection Monday-Friday over two weeks; followed by a |
| Active, not recruiting |
Study Name: Evaluation and Treatment of Tall Statured Girls Condition: Constitutional Tall Stature Date: 2015-12-13 Interventions: Drug: Estradiol Estradiol containing compounds administered orally in a non-randomized manner. |
| Recruiting |
Study Name: High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant Condition: T-cell Lymphoma Leukaemia Date: 2013-09-03 |
| Active, not recruiting |
Study Name: A Phase 2 Study of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma Condition: Adult T-Cell Leukemia-Lymphoma Date: 2012-11-07 Interventions: Drug: Lenalidomide 25 mg of Lenalidomide administered orally once daily |
| Recruiting |
Study Name: Ruxolitinib for Adult T-Cell Leukemia Condition: T Cell Leukemia, Adult Leukemia, Adult T-Cell T Cell Leuke Date: 2012-10-20 Interventions: Drug: Ruxolitinib Ruxolitinib 20 mg orally twice daily for 28 days. Patient may continue to receive trea |
| Active, not recruiting |
Study Name: KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL) Condition: Adult T-cell Leukemia-Lymphoma Date: 2012-06-19 Interventions: Biological: KW-0761 1.0 mg/kg |
| Completed |
Study Name: Trial to Assess Effect of Raltegravir on HTLV-1 Proviral Load Condition: Human T-cell Leukemia Virus Type 1 Infection Date: 2012-01-25 Interventions: Drug: Raltegravir Raltegravir 400 mg po bid |
| Completed |
Study Name: Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab) Condition: HTLV-I Associated Adult T-cell Leukaemia/Lymphoma (ATLL) Date: 2011-08-16 Interventions: Drug: CHOP-daclizumab Other Name: CHOP-Zenapax |